|Bid||54.79 x 900|
|Ask||54.80 x 800|
|Day's Range||53.74 - 54.85|
|52 Week Range||42.14 - 66.41|
|Beta (3Y Monthly)||1.34|
|PE Ratio (TTM)||57.19|
|Earnings Date||Jul 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.08|
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLAINSBORO, N.J., July 10, 2019 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2019.
Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.
BALTIMORE , July 8, 2019 /PRNewswire/ -- Integra LifeSciences, a leading global medical technology company, is pleased to announce a pioneering partnership with Tissue Analytics , an AI-powered software ...
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...
Integra LifeSciences Holdings Corporation (IART), a leading global medical technology company, today announced the promotion of Glenn Coleman to the newly-created role of chief operating officer (COO) and appointed Carrie Anderson as chief financial officer (CFO), effective June 24, 2019. “Having doubled the size of our business over the past several years and nearly completing the transformational Codman acquisition integration, we have reached a critical inflection in Integra’s history,” said Peter Arduini, president & chief executive officer, Integra LifeSciences. “Looking at the opportunities ahead, the creation of the COO role will provide the oversight we need to accelerate our future growth. The move will also allow me to focus greater attention on our long-term strategic direction and spend more time with our customers. I’m also excited to welcome Carrie to Integra.
Today we will run through one way of estimating the intrinsic value of Integra LifeSciences Holdings Corporation...
In this article we are going to estimate the intrinsic value of Integra LifeSciences Holdings Corporation...
Investors are always looking for growth in small-cap stocks like Integra LifeSciences Holdings Corporation...
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Examining Integra LifeSciences Holdings Corporation's (NASDAQ:IART) past track record of performance is a useful...
Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.
Integra LifeSciences Holdings Corp NASDAQ/NGS:IARTView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for IART with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding IART totaled $255 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
It hasn't been the best quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART) shareholders, since the...
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PLAINSBORO, N.J., May 23, 2019 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following.
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Integra LifeSciences Holdings Corporation (NASDAQ:IART), which is in the med...
PLAINSBORO, N.J., April 30, 2019 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following.